Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 2033 (LINC02033)
- Target
- LINC02033
- Molecular classification
- Long non-coding RNA (lncRNA), Long intergenic non-coding RNA (lincRNA), Other (non-coding RNA)
01
Overview
Long intergenic non-protein coding RNA 2033 (LINC02033) is a member of the long intergenic non-coding RNAs (lincRNAs), a class of long non-coding RNAs longer than 200 nucleotides that are located between protein-coding genes and do not overlap known coding loci. lincRNAs, including LINC02033, are involved in regulating gene expression—sometimes through chromatin remodeling, acting as enhancers, modulating transcription, or via interactions with microRNAs or proteins. While the general class of lincRNAs has demonstrated tissue-specific expression patterns and a range of important functions—including roles in development, cell cycle regulation, and carcinogenesis—the specific biological function, disease relevance, and therapeutic targeting potential of LINC02033 remain incompletely characterized in current scientific literature.
- Other names
- LINC02033
02
Mechanism of action
Not applicable; LINC02033 is not a classical druggable target and no targeted drugs are reported
03
Biological functions
Chromatin remodeling and genome architecture modulation (by analogy to other lincRNAs)Transcriptional regulation (including local gene regulation in cis, and enhancer-like activity)Fine-tuning expression of neighboring genesPossible involvement in cell cycle, cell proliferation, or apoptosis (analogous to lincRNAs as a class; specific function for LINC02033 not directly described in current sources)
04
Disease associations
Cancer (lincRNAs in general, and LINC02033 specifically, have been associated with various cancers; exact role may be cancer-type specific but is incompletely characterized)Other (potential tissue-specific roles; no confirmed major role outside of cancer as of current knowledge)
05
Safety considerations
Not established. As an RNA, therapeutic targeting (e.g., by antisense oligonucleotides) would raise general concerns about off-target effects, delivery, and specificity, which are common to all lncRNA-targeting therapeutics
06
Biomarkers
None established for clinical use. Some lincRNAs act as prognostic or diagnostic biomarkers especially in cancer, but data for LINC02033 as a biomarker is lacking as of current literature
Beyond the preview
Go deeper on Long intergenic non-protein coding RNA 2033 (LINC02033).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Long intergenic non-protein coding RNA 2033 (LINC02033).